文献速递免疫规划传染病防控与疫情报告

瑞士成人蜱传脑炎疫苗接种覆盖率与依从性分析

Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018.
PubMed 文献 · Vaccine · 2020-10-21

2018年瑞士全国横断面调查评估18-79岁成人蜱传脑炎(TBE)疫苗接种覆盖率与依从性。全国1剂覆盖率41.7%(范围14.3%-60.3%),3剂基础系列覆盖率32.9%(范围8.4%-50.4%),估算疫苗有效性91.5%(95%CI:90.9-92.0%),2018年预防135例(95%CI:112-162)TBE病例。

要点

  • 瑞士成人TBE疫苗1剂覆盖率41.7%,3剂基础系列覆盖率32.9%,地区差异大。
  • 估算疫苗有效性91.5%(95%CI:90.9-92.0%),未接种成人发病率6.83/10万。
  • 有蜱虫相关健康问题经历、常接触自然或感知风险高者更可能接种至少1剂。

核心结论

  • 瑞士成人TBE疫苗接种覆盖率存在较大地区差异,且与各州疾病发病率显著相关。
  • 提升公众对TBE健康影响和风险因素的认知可能有助于改善接种覆盖率,但干预措施需考虑接种率的异质性。

研究设计与样本

  • 2018年瑞士全国横断面调查,基于疫苗接种卡评估18-79岁成人TBE疫苗接种覆盖率与依从性。

主要发现

  • 全国TBE疫苗1剂覆盖率为41.7%(范围14.3%-60.3%),3剂基础系列覆盖率为32.9%(范围8.4%-50.4%)。
  • 各州2009-2018年平均疾病发病率与1剂和3剂疫苗覆盖率均呈显著相关。
  • 总体人群中9.5%至少接种过1剂TBE加强针,地区覆盖率差异大。
  • 估算23%的瑞士成人基于接种史可获得保护,2018年预防135例(95%CI:112-162)TBE病例。
  • 未接种成人TBE发病率为6.83/10万,估算疫苗有效性为91.5%(95%CI:90.9-92.0%)。

关键数值与推荐

  • 全国1剂TBE疫苗覆盖率41.7%(范围14.3%-60.3%),3剂基础系列覆盖率32.9%(范围8.4%-50.4%)。
  • 至少接种1剂加强针的比例为9.5%,地区差异大。
  • 估算疫苗有效性91.5%(95%CI:90.9-92.0%),未接种成人发病率6.83/10万。
  • 2018年估算预防135例(95%CI:112-162)TBE病例。

临床怎么用

  • 应针对不同地区接种率异质性制定差异化公共卫生干预策略。
  • 推广TBE健康影响和风险因素的知识可能提升疫苗接种依从性。
  • 临床中可识别有蜱虫相关健康问题经历或高频自然暴露的成人,促进其接种TBE疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall incidence and geographic range of Tick-borne Encephalitis (TBE), a vaccine preventable infection, have steadily increased in Switzerland over the last 50 years. While fully subsidized vaccination has been recommended in many areas for well over a decade, vaccine coverage and variables associated with vaccination compliance among Swiss adults are poorly understood. METHODS: In 2018 we conducted a national, cross-sectional survey of vaccination cards evaluating TBE vaccination coverage and compliance among adults (18-79) in Switzerland. RESULTS: Nationwide TBE vaccination coverage was 41.7% (range 14.3% to 60.3%) for 1 dose and 32.9% (range 8.4% to 50.4%) for a complete primary series (3 doses). There was a significant correlation between average disease incidence by canton (2009-2018) and vaccine coverage at both 1 and 3 doses. Of the overall population, 9.5% had received at least one TBE booster vaccination with large regional coverage variation. We estimated that 23% of adults in Switzerland would be protected from infection based on their vaccination history and 135 (95% CI: 112-162) TBE cases were prevented in 2018. Individuals reporting previous experience with tick-associated health problems, those frequently in nature or those with "high" perceived risk of contracting TBE, were significantly more likely to have received at least one vaccine dose, indicating a positive impact of awareness on vaccination compliance. We also calculated a TBE incidence rate of 6.83/100,000 among the unvaccinated adult population in Switzerland and estimated vaccine effectiveness at 91.5% (95% CI: 90.9-92.0%). CONCLUSIONS: These findings provide an important reference for TBE vaccination levels in Switzerland and further suggest that public health interventions promoting knowledge of TBE health impacts and risk factors may be beneficial in improving TBE vaccination coverage but should be tailored to account for heterogeneity in vaccine uptake.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Baroutsou V, Zens KD, Sinniger P, et al. Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018. Vaccine. 2020. PMID: 33164805. doi:10.1016/j.vaccine.2020.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。